Hematogenix
Khairul Faizi Khalid, MD, is an accomplished medical professional and operations leader with extensive experience in the healthcare sector. Currently serving as the Director and Operations Manager for Hematogenix in the Asia Pacific region since March 2019, Khairul has been instrumental in establishing APAC operations. As Managing Director and Co-Founder of remedi, the company has expanded significantly, serving nearly 500 primary care clinics. Previous roles include Head of Business Development at Clinical Research Malaysia, where Khairul implemented key projects to enhance clinical trials in the country, and Board Member at Mahsuri Private Maternity Hospital, leading its transformation into a profitable entity. Experience also includes positions at Boehringer Ingelheim and AstraZeneca, focusing on cardiovascular and metabolic product management. Khairul began medical career as a Medical Officer in the Ministry of Health Malaysia, showcasing a diverse background in clinical medicine and operational management. Education includes a Doctor of Medicine from First Moscow State Medical University and a certificate in Russian Language and Literature from Universiti Teknologi MARA.
This person is not in any offices
Hematogenix
1 followers
Hematogenix, a global cancer-focused life science company serving the pharmaceutical & biotechnology industry as well as community physicians. With passionate scientists and board-certified clinical and anatomic pathologists and hematopathologists from around the world, Hematogenix offers an array of biomarker development and testing services navigating the complexities of human diseases and clinical trials. Our global team of scientists provides reference laboratory services at our facilities around the globe: in the US, Europe, China, and Asia-Pacific. We are uniquely equipped to help clients accelerate cancer research and drug development efforts at these globally connected facilities. Hematogenix provides a complete menu of services such as Flow Cytometry, Molecular Genetics, Next Generation Sequencing (NGS), Histology / Immunohistochemistry (IHC), Cytogenetics / FISH, Pathology, Digital Pathology and Image Analysis. Our test menu reflects our commitment to utilizing the most advanced techniques to enhance patient care. We provide customized services ranging from the initial stages of research to development, and extending all the way to the implementation of targeted therapies in the clinical setting. * CAP – Accredited * CLIA – Certified * GCP – Compliant